Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci - PubMed (original) (raw)
Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci
I González et al. Antimicrob Agents Chemother. 1998 Nov.
Abstract
The nucleotide sequences of the quinolone resistance-determining regions (QRDRs) of the parC and gyrA genes from seven ciprofloxacin-resistant (Cpr) isolates of viridans group streptococci (two high-level Cpr Streptococcus oralis and five low-level Cpr Streptococcus mitis isolates) were determined and compared with those obtained from susceptible isolates. The nucleotide sequences of the QRDRs of the parE and gyrB genes from the five low-level Cpr S. mitis isolates and from the NCTC 12261 type strain were also analyzed. Four of these low-level Cpr isolates had changes affecting the subunits of DNA topoisomerase IV: three in Ser-79 (to Phe or Ile) of ParC and one in ParE at a position not previously described to be involved in quinolone resistance (Pro-424). One isolate did not show any mutation. The two high-level Cpr S. oralis isolates showed mutations affecting equivalent residue positions of ParC and GyrA, namely, Ser-79 to Phe and Ser-81 to Phe or Tyr, respectively. The parC mutations were able to transform Streptococcus pneumoniae to ciprofloxacin resistance, while the gyrA mutations transformed S. pneumoniae only when mutations in parC were present. These results suggest that DNA topoisomerase IV is a primary target of ciprofloxacin in viridans group streptococci, DNA gyrase being a secondary target.
Figures
FIG. 1
Comparison of the nucleotide sequences of a region of parC containing the QRDRs from S. pneumoniae R6 (SPN R6) and various strains of S. oralis (SOR) and S. mitis (SMI). R1(3180C) is M22 transformed to the first level of ciprofloxacin resistance by use of the parC50-152 PCR product from strain 3180. Nucleotides and amino acids (italics) are numbered by taking the first parC nucleotide as nt 1 and the first ParC residue as number 1. The strand corresponding to the mRNA is shown. Only nucleotides different from those of S. pneumoniae R6 are indicated; dashes indicate nucleotide identity. Sense mutations and the corresponding amino acid changes are shown in bold. The deduced amino acid sequence of S. pneumoniae R6 is shown at the bottom, together with the amino acid changes observed in the indicated strains (in parentheses).
FIG. 2
Comparison of the nucleotide sequences of a region of gyrA containing the QRDRs from S. pneumoniae R6 (SPN R6) and various strains of S. oralis (SOR) and S. mitis (SMI). R2(3429C/3180A) and R2(3429C/3870A) are R13429C (25) transformed to the second level of ciprofloxacin resistance by use of the gyrA46-172 PCR products from strains 3180 and 3870, respectively. Nucleotides and amino acids (italics) are numbered by taking the first gyrA nucleotide as nt 1 and the first GyrA residue as number 1. Symbols are as defined in the legend to Fig. 1.
FIG. 3
Comparison of the nucleotide sequences of regions of parE (A) and gyrB (B) containing the QRDRs from S. pneumoniae R6 (SPN R6) and various strains of S. mitis (SMI). Nucleotides and amino acids (italics) are numbered by taking the first parE or gyrB nucleotide as nt 1 and the first ParE or GyrB residue as number 1. Symbols are as defined in the legend to Fig. 1.
Similar articles
- Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.
Jorgensen JH, Weigel LM, Ferraro MJ, Swenson JM, Tenover FC. Jorgensen JH, et al. Antimicrob Agents Chemother. 1999 Feb;43(2):329-34. doi: 10.1128/AAC.43.2.329. Antimicrob Agents Chemother. 1999. PMID: 9925527 Free PMC article. - Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
Pan XS, Fisher LM. Pan XS, et al. J Bacteriol. 1996 Jul;178(14):4060-9. doi: 10.1128/jb.178.14.4060-4069.1996. J Bacteriol. 1996. PMID: 8763932 Free PMC article. - Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.
Pan XS, Ambler J, Mehtar S, Fisher LM. Pan XS, et al. Antimicrob Agents Chemother. 1996 Oct;40(10):2321-6. doi: 10.1128/AAC.40.10.2321. Antimicrob Agents Chemother. 1996. PMID: 8891138 Free PMC article. - DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
Pan XS, Fisher LM. Pan XS, et al. Antimicrob Agents Chemother. 1998 Nov;42(11):2810-6. doi: 10.1128/AAC.42.11.2810. Antimicrob Agents Chemother. 1998. PMID: 9797208 Free PMC article. - ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.
Muñoz R, De La Campa AG. Muñoz R, et al. Antimicrob Agents Chemother. 1996 Oct;40(10):2252-7. doi: 10.1128/AAC.40.10.2252. Antimicrob Agents Chemother. 1996. PMID: 8891124 Free PMC article.
Cited by
- Streptococcus mutans clonal variation revealed by multilocus sequence typing.
Nakano K, Lapirattanakul J, Nomura R, Nemoto H, Alaluusua S, Grönroos L, Vaara M, Hamada S, Ooshima T, Nakagawa I. Nakano K, et al. J Clin Microbiol. 2007 Aug;45(8):2616-25. doi: 10.1128/JCM.02343-06. Epub 2007 Jun 13. J Clin Microbiol. 2007. PMID: 17567784 Free PMC article. - Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain.
de la Campa AG, Balsalobre L, Ardanuy C, Fenoll A, Pérez-Trallero E, Liñares J; Spanish Pneumococcal Infection Study Network G03/103. de la Campa AG, et al. Emerg Infect Dis. 2004 Oct;10(10):1751-9. doi: 10.3201/eid1010.040382. Emerg Infect Dis. 2004. PMID: 15504260 Free PMC article. - Mosaic genes and mosaic chromosomes: intra- and interspecies genomic variation of Streptococcus pneumoniae.
Hakenbeck R, Balmelle N, Weber B, Gardès C, Keck W, de Saizieu A. Hakenbeck R, et al. Infect Immun. 2001 Apr;69(4):2477-86. doi: 10.1128/IAI.69.4.2477-2486.2001. Infect Immun. 2001. PMID: 11254610 Free PMC article. - Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.
Balsalobre L, de la Campa AG. Balsalobre L, et al. Antimicrob Agents Chemother. 2008 Mar;52(3):822-30. doi: 10.1128/AAC.00731-07. Epub 2007 Dec 26. Antimicrob Agents Chemother. 2008. PMID: 18160515 Free PMC article. - Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci.
Guerin F, Varon E, Hoï AB, Gutmann L, Podglajen I. Guerin F, et al. Antimicrob Agents Chemother. 2000 Aug;44(8):2197-200. doi: 10.1128/AAC.44.8.2197-2200.2000. Antimicrob Agents Chemother. 2000. PMID: 10898702 Free PMC article.
References
- Belland R, Morrison S, Ison C, Huang W. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol Microbiol. 1994;14:371–380. - PubMed
- Bochud P Y, Eggiman P H, Calandra T H, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 1994;18:25–31. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources